Phase 2a, Open-Label, 4-Escalating-Dose, Randomized Multicenter Study Evaluating the Safety and Activity of Ferroquine (SSR97193) Plus Artesunate, versus Amodiaquine Plus Artesunate, in African Adult Men with Uncomplicated Plasmodium falciparum Malaria

Autor: Cantalloube C, Bernhards Ogutu, Otsula N, Peter G. Kremsner, Apollo D, Walsh Ds, Elhadj Djeriou, Christian Supan, Ghyslain Mombo-Ngoma, John N. Waitumbi, Mark E. Polhemus, Bertrand Lell, Ospina Salazar Cl, Maryvonne Kombila, Jana Held

Publikováno v: The American Journal of Tropical Medicine and Hygiene. 97:514-525

Artemisinin-based combination therapies are recommended as first-line agents for treating uncomplicated Plasmodium falciparum malaria. Ferroquine, a 4-aminoquinolone, is a novel long-acting combination partner for fast-acting drugs like artesunate (A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::190a3698fb7436eff546231f74cbb659
https://doi.org/10.4269/ajtmh.16-0731

Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres.

Autor: Mordmüller B; Institut für Tropenmedizin, Eberhard Karls Universität Tübingen and German Center for Infection Research, 72074, Tübingen, Germany. benjamin.mordmueller@uni-tuebingen.de., Supan C; Institut für Tropenmedizin, Eberhard Karls Universität Tübingen and German Center for Infection Research, 72074, Tübingen, Germany. christian.supan@medizin.uni-tuebingen.de., Sim KL; Sanaria Inc, Rockville, MD, 20850, USA. ksim@protpot.com., Gómez-Pérez GP; Barcelona Center for International Health Research (CRESIB), Hospital Clínic, University of Barcelona, E-08036, Barcelona, Spain. patricia.gomez@cresib.cat., Ospina Salazar CL; Institut für Tropenmedizin, Eberhard Karls Universität Tübingen and German Center for Infection Research, 72074, Tübingen, Germany. carmenlucelly@hotmail.com., Held J; Institut für Tropenmedizin, Eberhard Karls Universität Tübingen and German Center for Infection Research, 72074, Tübingen, Germany. janaheld@hotmail.de., Bolte S; Institut für Tropenmedizin, Eberhard Karls Universität Tübingen and German Center for Infection Research, 72074, Tübingen, Germany. stefanie.bolte@web.de., Esen M; Institut für Tropenmedizin, Eberhard Karls Universität Tübingen and German Center for Infection Research, 72074, Tübingen, Germany. meral.esen@uni-tuebingen.de., Tschan S; Institut für Tropenmedizin, Eberhard Karls Universität Tübingen and German Center for Infection Research, 72074, Tübingen, Germany. serena.tschan@gmail.com., Joanny F; Institut für Tropenmedizin, Eberhard Karls Universität Tübingen and German Center for Infection Research, 72074, Tübingen, Germany. fanny.joanny@gmail.com., Lamsfus Calle C; Institut für Tropenmedizin, Eberhard Karls Universität Tübingen and German Center for Infection Research, 72074, Tübingen, Germany. carlos.lamsfus@gmail.com., Löhr SJ; Institut für Tropenmedizin, Eberhard Karls Universität Tübingen and German Center for Infection Research, 72074, Tübingen, Germany. sascha-zori-loehr@web.de., Lalremruata A; Institut für Tropenmedizin, Eberhard Karls Universität Tübingen and German Center for Infection Research, 72074, Tübingen, Germany. albrt.04@gmail.com., Gunasekera A; Sanaria Inc, Rockville, MD, 20850, USA. agunasekera@sanaria.com., James ER; Sanaria Inc, Rockville, MD, 20850, USA. ejames@sanaria.com., Billingsley PF; Sanaria Inc, Rockville, MD, 20850, USA. pbillingsley@sanaria.com., Richman A; Sanaria Inc, Rockville, MD, 20850, USA. arichman@sanaria.com., Chakravarty S; Sanaria Inc, Rockville, MD, 20850, USA. schakravarty@sanaria.com., Legarda A; Barcelona Center for International Health Research (CRESIB), Hospital Clínic, University of Barcelona, E-08036, Barcelona, Spain. almudena.legarda@gmail.com., Muñoz J; Barcelona Center for International Health Research (CRESIB), Hospital Clínic, University of Barcelona, E-08036, Barcelona, Spain. jmunozg@clinic.ub.es., Antonijoan RM; Drug Research Center (CIM), Institute of Biomedical Research (IIB), Research Institute of Santa Creu and Sant Pau Hospital, Barcelona, Spain. rantonijoana@santpau.cat.; Department of Pharmacology and Therapeutics, Autonomous University of Barcelona (UAB), Santa Creu and Sant Pau Hospital, E-08026, Barcelona, Spain. rantonijoana@santpau.cat., Ballester MR; Drug Research Center (CIM), Institute of Biomedical Research (IIB), Research Institute of Santa Creu and Sant Pau Hospital, Barcelona, Spain. mballesterv@santpau.cat.; Department of Pharmacology and Therapeutics, Autonomous University of Barcelona (UAB), Santa Creu and Sant Pau Hospital, E-08026, Barcelona, Spain. mballesterv@santpau.cat., Hoffman SL; Sanaria Inc, Rockville, MD, 20850, USA. slhoffman@sanaria.com., Alonso PL; Barcelona Center for International Health Research (CRESIB), Hospital Clínic, University of Barcelona, E-08036, Barcelona, Spain. pedro.alonso@isglobal.org., Kremsner PG; Institut für Tropenmedizin, Eberhard Karls Universität Tübingen and German Center for Infection Research, 72074, Tübingen, Germany. peter.kremsner@uni-tuebingen.de.

Publikováno v: Malaria journal [Malar J] 2015 Mar 18; Vol. 14, pp. 117. Date of Electronic Publication: 2015 Mar 18.

Phase I randomized dose-ascending placebo-controlled trials of ferroquine--a candidate anti-malarial drug--in adults with asymptomatic Plasmodium falciparum infection.

Autor: Mombo-Ngoma G; Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon., Supan C, Dal-Bianco MP, Missinou MA, Matsiegui PB, Ospina Salazar CL, Issifou S, Ter-Minassian D, Ramharter M, Kombila M, Kremsner PG, Lell B

Publikováno v: Malaria journal [Malar J] 2011 Mar 01; Vol. 10, pp. 53. Date of Electronic Publication: 2011 Mar 01.